Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 101Central Nervous System Neoplasms 37Medulloblastoma 35Brain Neoplasms 33Glioblastoma 20Sarcoma 16Rhabdoid Tumor 14Glioma 13Ependymoma 12Astrocytoma 11Osteosarcoma 10Neuroectodermal Tumors, Primitive 10Recurrence 9Neoplasms 9Lymphoma 9Breast Neoplasms 9Sarcoma, Ewing 8Oligodendroglioma 8Melanoma 8Ganglioneuroblastoma 8Choroid Plexus Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Leukemia, Myeloid, Acute 7Gliosarcoma 7Rhabdomyosarcoma 6Multiple Myeloma 6Wilms Tumor 5

Interventions

Vincristine 1Radiotherapy 1Pemetrexed 1Neuropsychological Tests 1HhAntag691 1Gemcitabine 1Exercise 1Cyclophosphamide 1Craniospinal Irradiation 1Control Groups 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infratentorial Neoplasms × Cyclophosphamide × CNS × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡